Drug intelligence / Profile preview

ohmefentanyl

Development stage
Unknown
Modality
Small Molecules
01

Overview

Ohmefentanyl is an extremely potent synthetic opioid analgesic belonging to the fentanyl family. It acts as a highly selective agonist of the μ-opioid receptor, producing profound analgesia and effects similar to other opioids but at much lower doses. Ohmefentanyl is notable for its extraordinary potency—mouse studies show it can be up to 28 times more powerful than fentanyl and approximately 6,300 times more potent than morphine. The compound has three stereogenic centers, resulting in eight possible stereoisomers (F9201–F9208), each with distinct pharmacological profiles; some analogues are even more potent than ohmefentanyl itself. Like other fentanyl analogues, side effects include itching, nausea, and potentially fatal respiratory depression. Ohmefentanyl has no accepted medical use in most countries and is classified as a Schedule I controlled substance due to its high potential for abuse and lack of safety under medical supervision[1][2][3][10].

Other names
beta-hydroxy-3-methylfentanylbeta-hydroxy3-methylfentanylbeta-hydroxy 3-methylfentanylβ-hydroxy-3-methylfentanyl
02

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on ohmefentanyl.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ohmefentanyl.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call